Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report.

Abstract

Type I hypersensitivity reactions to intravenous administration of etoposide are extremely rare. Etoposide is an essential component of several chemotherapy regimens used in gynecologic oncology, and discontinuation of this drug during a course of treatment should only be due to severe patient intolerance. We report the successful use of intravenous etoposide phosphate as a substitute drug in a patient with a yolk sac tumor who manifested a Type I hypersensitivity to intravenous etoposide. The patient ultimately completed all 4 cycles of bleomycin, etoposide, cisplatin (BEP) using etoposide phosphate as a substitute drug.

• Authors: David Starks, Deborah Prinz, Amy Armstrong, Lindsay Means, Steven Waggoner, Robert Debernardo
• Journal: Case reports in obstetrics and gynecology (Case Rep Obstet Gynecol) Vol. 2011 Pg. 837160 ( 2011) ISSN: 2090-6692 [Electronic] United States
• PMID: 22567517 (Publication Type: Case Reports)